Deep divefrom Episode 3TrainingLongevity2 September 202615 min

Does Lifelong Sports Participation Protect Against Sarcopeni

A deep dive into one paper: what was known before, what the researchers did, what the numbers say and what they don't.

The paper: Does Lifelong Sports Participation Protect Against Sarcopenia? (Quality in Sport)

Chapters

Transcript

The script the two AI voices read from. The times are worked out from the script, not heard, so a line can start a few seconds early or late.

Read the whole episode

Cold open

Host 1Welcome to the Hastrup Review of Science — where artificial intelligence reads real science, so you don't have to pretend you understood the paper. One paper today. Everyone loses muscle as they age. But masters athletes — the people who keep competing into their forties, fifties, sixties and beyond — seem to lose it more slowly. A new scoping review asks how much protection lifelong sport actually provides, and whether the type of sport matters.

Host 2Olszowiec and colleagues have mapped the available evidence on sarcopenia prevalence, diagnostic criteria, and sport-specific muscle outcomes in masters athletes and former elite athletes. The review follows JBI scoping review guidance and the PRISMA-ScR checklist. The paper is published in Quality in Sport.

What is sarcopenia

Host 1The paper is called Does Lifelong Sports Participation Protect Against Sarcopenia. Before we get into their findings, what exactly is sarcopenia?

Host 2Sarcopenia is the age-related loss of skeletal muscle mass, strength, and physical function. The word comes from the Greek — sarx for flesh and penia for poverty. It was coined in 1989 by Irwin Rosenberg, who argued that no single feature of age-related decline was more striking than the loss of lean body mass.

Host 1And it is now a recognised medical condition, not just a natural part of aging.

Host 2It received its own ICD-10 code in 2016. That was significant because it reframed sarcopenia from an inevitable consequence of getting older into a diagnosable, potentially treatable condition. After about age thirty, adults lose roughly three to eight percent of their muscle mass per decade, and the rate accelerates after sixty. By age eighty, many people have lost thirty to fifty percent of their peak muscle mass.

The diagnostic mess

Host 1But diagnosing it is not straightforward. The paper emphasises that different diagnostic frameworks give very different answers.

Host 2This is one of the most important themes in the review. The European Working Group on Sarcopenia in Older People, known as EWGSOP2, published updated criteria in 2019. They use a stepwise approach: low grip strength identifies probable sarcopenia, confirmation requires demonstrated low muscle quantity or quality, and it becomes severe sarcopenia if physical performance is also impaired.

Host 1And other groups use different criteria?

Host 2Substantially different. The Asian Working Group for Sarcopenia uses different cutpoints optimised for Asian populations. The Foundation for the National Institutes of Health criteria weight grip strength relative to BMI. The Sarcopenia Definitions and Outcomes Consortium emphasises grip strength and gait speed but deliberately excludes muscle mass from the definition. Depending on which framework you apply to the same population, prevalence estimates can differ by a factor of five or more.

Host 1So the question how common is sarcopenia in athletes does not have a single answer.

Host 2The review makes this point explicitly: comparing prevalence across studies is only meaningful when you account for the diagnostic framework used, the measurement method for muscle quantity, and the cutpoints applied. This sounds like a methodological footnote, but it has real consequences. An endurance athlete could be classified as sarcopenic under one set of criteria and perfectly healthy under another.

Masters athletes

Host 1Who counts as a masters athlete in this review?

Host 2They included competitive masters athletes, lifelong exercisers, former elite athletes, and former Olympians aged forty years or older. Masters athletes are people who continue to train and compete in organised sport well beyond the typical age of peak athletic performance.

Host 1They are a kind of natural experiment.

Host 2They are. If you want to know how much of age-related muscle loss is biologically inevitable versus caused by decades of sedentary behaviour, masters athletes are the closest comparison you can get. They have been physically active for decades. They train systematically. And they provide a contrast to the general population, where declining physical activity and muscle loss are deeply entangled.

Prevalence

Host 1So what did the review find? How common is sarcopenia in athletes compared to everyone else?

Host 2Across the studies included, athletes consistently showed a lower prevalence of confirmed sarcopenia than community-dwelling older adults. In community populations, depending on the criteria used, sarcopenia prevalence in people over sixty-five typically ranges from about ten to twenty-seven percent. In the athlete populations studied, confirmed sarcopenia was consistently rare.

Host 1Rare meaning what?

Host 2In several studies it was below five percent, and in some strength-sport populations it was essentially absent. But the review is careful to note that direct numerical comparison is hazardous because the studies used different criteria, different populations, and different measurement methods. The direction of the finding is consistent — athletes do better — but the magnitude of the gap depends heavily on the diagnostic framework.

Sport-specific differences

Host 1The most interesting finding, to me, is that not all sports protect equally. A lifelong runner and a lifelong weightlifter are aging differently.

Host 2That is the central finding. Strength and sprint athletes generally displayed greater appendicular lean mass, higher maximal strength, faster rate of force development, and better preservation of type two muscle fibres compared to endurance athletes.

Host 1Appendicular lean mass is the muscle in your arms and legs?

Host 2It is the lean tissue in your limbs specifically, as distinct from the trunk. It is the standard measurement used in sarcopenia definitions because limb muscle is what drives locomotion, balance, and the ability to rise from a chair — the functional tasks that determine whether someone can live independently.

The type two fibre problem

Host 1And type two fibres — the fast-twitch fibres. Why do those matter so much in this context?

Host 2One of the hallmark features of muscle aging is the preferential loss of type two fibres. There are broadly two categories. Type one fibres are slow-twitch, fatigue-resistant, and primarily support sustained endurance activities. Type two fibres are fast-twitch, generate force rapidly, and are responsible for powerful, explosive movements — sprinting, jumping, catching yourself when you trip.

Host 1Why does the body lose the fast-twitch fibres first?

Host 2The mechanism involves motor unit remodelling. As you age, the motor neurons that innervate type two fibres progressively die. When a type two fibre loses its motor neuron, a surviving type one motor neuron may reinnervate it, effectively converting it. The result is a gradual shift in fibre composition toward slow-twitch, with a loss of the fast, powerful contractions that type two fibres provide.

Host 1And that matters practically because?

Host 2Because power — the ability to generate force quickly — declines faster than strength with age. And power is what you need to catch yourself when you stumble, to climb stairs efficiently, to get up from a low seat. Studies in older adults consistently show that muscle power is a better predictor of functional independence and fall risk than maximal strength alone.

Host 1So the review is saying that strength and power athletes preserve exactly the fibre type that aging preferentially destroys.

Host 2That is the pattern. The high-force, high-velocity demands of strength and sprint training appear to provide a stimulus that maintains type two fibre size and function. Endurance training, while conferring many other health benefits, does not impose the same demands on fast-twitch motor units and therefore does not protect them to the same degree.

A word from our sponsor

Host 1Have you noticed that aging takes things you want — like muscle — and replaces them with things you did not ask for? Like nose hair?

Host 2The Hastrup Review of Science is brought to you by nose-hair trimmers. A targeted intervention for unwanted follicular overgrowth.

Host 1I want to be clear: this is the one area where age-related decline is not the problem. Your nose hair is thriving. It is the only tissue in your body that shows no signs of sarcopenia.

Host 2Type two fibres may be in decline, but your nasal follicles are operating at peak capacity. Consider a trim.

Host 1Nose-hair trimmers. Because some things should not grow unchecked, even if your fast-twitch fibres will not. Our referral link is in the show notes.

Endurance athletes

Host 1Back to the findings. The review did not dismiss endurance athletes. What did lifelong endurance training actually preserve?

Host 2Lifelong endurance training was associated with low adiposity, superior aerobic capacity, favourable muscle oxidative characteristics, and in several studies preserved muscle quality — meaning the force produced per unit of muscle mass. Endurance athletes also tend to maintain better cardiovascular function and insulin sensitivity than sedentary peers of the same age.

Host 1But there were gaps.

Host 2Endurance training did not fully prevent lower muscle mass, motor unit loss, or age-related reductions in power. The review found that older endurance athletes often had muscle mass values that were lower than those of strength athletes and sometimes comparable to non-athletes of similar age and body size, despite having far better aerobic fitness and lower body fat.

Host 1So a seventy-year-old marathon runner might have excellent cardiovascular health but still be at risk for low muscle mass?

Host 2That is a possibility the review raises. And it highlights a practical tension: if you screen for sarcopenia using criteria that emphasise muscle mass, endurance athletes may look vulnerable. If you use criteria that emphasise physical performance — gait speed, chair-stand tests — the same endurance athletes may look excellent. The diagnostic framework you choose can determine whether the same person is classified as sarcopenic or robust.

Keep training

Host 1One of the most striking conclusions is that what you do now matters more than what you did before.

Host 2Continued training after elite retirement appeared more important than historical athletic status alone. Former elite athletes who stopped training showed muscle characteristics that were closer to sedentary controls than to masters athletes who had continued competing. The athletic history provided some residual advantage, but it was modest compared to the effect of ongoing training.

Host 1So being a former Olympian does not give you a permanent muscle advantage.

Host 2Not a large one, according to this evidence. The muscle system is highly responsive to current demand. If you stop imposing a stimulus, the adaptations reverse. This is consistent with the basic physiology of skeletal muscle: it is arguably the most plastic organ in the body in terms of responding to mechanical loading. The protective effect of sport against sarcopenia appears to be predominantly an effect of current activity, not a permanent legacy of past achievement.

Caveats

Host 1What should we be cautious about in this review?

Host 2Several things. First, this is a scoping review, not a systematic review or meta-analysis. Its purpose is to map the breadth of available evidence and identify gaps. It does not pool effect sizes, does not apply formal risk-of-bias assessment to included studies, and does not generate quantitative estimates of how much sport reduces sarcopenia risk. It tells you what has been studied and what the general patterns are, not the precise magnitude of any effect.

Host 1Second?

Host 2Survivorship bias. Masters athletes who continue competing into their sixties and seventies are a self-selected population. They may have been genetically predisposed to higher muscle mass, lower injury rates, and greater training tolerance from the start. The review cannot distinguish between the protective effect of training and the selection effect of who is able to keep training for decades.

Host 1People who still have good muscles at seventy may be the people who were always going to have good muscles at seventy.

Host 2That is the concern. You would need longitudinal studies that follow people from early adulthood through old age, tracking both their activity and their muscle outcomes, to properly disentangle genetics from training. Very few such studies exist.

Host 1Third?

Host 2Most of the included studies are cross-sectional. They measured athletes and non-athletes at one time point and compared them. Very few tracked the same individuals over years or decades. That means we are inferring aging trajectories from snapshots, which is inherently less reliable than longitudinal data.

Host 1Fourth?

Host 2The diagnostic heterogeneity makes direct comparison across studies difficult. Different studies used different criteria, different measurement methods — DXA, BIA, MRI, CT — different cutpoints, and different reference populations. The review catalogues these differences carefully, but it cannot resolve them into a single coherent picture.

Host 1And the journal?

Host 2Quality in Sport is a peer-reviewed journal, but it is not a top-tier sports medicine outlet like the British Journal of Sports Medicine or Medicine and Science in Sports and Exercise. That does not mean the work is flawed — scoping reviews depend on search strategy and synthesis quality more than on novel data collection — but it is worth noting when assessing the visibility and external review this paper will receive.

Bottom line

Host 1What should someone take away from this?

Host 2Three things. First, lifelong sports participation substantially lowers the likelihood of clinical sarcopenia. The evidence is consistent across multiple studies and diagnostic frameworks. Sustained physical activity is the single most effective intervention we have against age-related muscle loss.

Host 1Second?

Host 2Training modality matters. If your goal is to preserve the muscle mass and fast-twitch fibre capacity that decline most aggressively with age, your training should include strength and power work. Endurance training provides enormous cardiovascular and metabolic benefits, but it does not substitute for the specific stimulus that heavy or explosive loading provides to type two fibres.

Host 1And third?

Host 2Keep training. A distinguished athletic career does not protect you if you stop. The body responds to current demand, not past achievement. What you are doing this decade matters more than what you did three decades ago.

Sign-off

Host 1That is the deep dive. Does Lifelong Sports Participation Protect Against Sarcopenia, from Olszowiec and colleagues, published in Quality in Sport. Link in the show notes.

Host 2This has been the Hastrup Review of Science. See you next week.